Physician profile
Jean Abed
NPI 1528371754
$6,899.20
in general payments reported to CMS, 2019-2025
31 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $446 · 2021: $1,245 · 2022: $1,050 · 2023: $871 · 2024: $1,364 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,687.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,297.87 | 2019-2025 | Mavyret, Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $833.80 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $620.46 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Gilead Sciences, INC. | $544.00 | 2019-2025 | |
| Madrigal Pharmaceuticals | $310.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $264.38 | 2019-2025 | Eohilia, Entyvio |
| Genzyme Corporation | $228.78 | 2022-2025 | |
| Celgene Corporation | $220.18 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $180.90 | 2024-2025 | Voquezna |
| Medtronic, INC. | $172.46 | 2023-2024 | Gi Genius |
| Bard Peripheral Vascular, INC. | $150.34 | 2023 | Venovo |
| Ironwood Pharmaceuticals, INC | $129.27 | 2020-2024 | Linzess |
| Qol Medical, LLC | $124.42 | 2019-2025 | Sucraid |
| Braintree Laboratories, INC. | $97.06 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $88.85 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $86.27 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $83.34 | 2019-2024 | Dificid |
| Pfizer INC. | $72.41 | 2021-2022 | |
| Redhill Biopharma INC. | $51.39 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $47.33 | 2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $43.86 | 2024 | Terlivaz |
| Daiichi Sankyo INC. | $43.01 | 2022 | |
| Ardelyx, INC. | $36.87 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $34.84 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $28.44 | 2024-2025 | Vowst |
| Celltrion USA INC. | $26.04 | 2025 | Vegzelma |
| Lilly USA, LLC | $22.79 | 2024 | Omvoh |
| Allergan, INC. | $19.96 | 2020 | |
| Ferring Pharmaceuticals INC. | $14.03 | 2024 | Rebyota |
| Amag Pharmaceuticals, INC. | $13.10 | 2022 | |
| Intercept Pharmaceuticals, INC. | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Abed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.